- Home
- EB vs TVTX Comparison
EB vs TVTX Comparison
Compare EB & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EB
- TVTX
- Stock Information
- Founded
- EB 2008
- TVTX 2008
- Country
- EB United States
- TVTX United States
- Employees
- EB N/A
- TVTX N/A
- Industry
- EB EDP Services
- TVTX Biotechnology: Pharmaceutical Preparations
- Sector
- EB Technology
- TVTX Health Care
- Exchange
- EB Nasdaq
- TVTX Nasdaq
- Market Cap
- EB 260.4M
- TVTX 1.1B
- IPO Year
- EB 2018
- TVTX N/A
- Fundamental
- Price
- EB $2.84
- TVTX $18.25
- Analyst Decision
- EB Buy
- TVTX Buy
- Analyst Count
- EB 6
- TVTX 13
- Target Price
- EB $6.70
- TVTX $20.85
- AVG Volume (30 Days)
- EB 1.3M
- TVTX 2.5M
- Earning Date
- EB 10-30-2024
- TVTX 11-05-2024
- Dividend Yield
- EB N/A
- TVTX N/A
- EPS Growth
- EB N/A
- TVTX N/A
- EPS
- EB N/A
- TVTX N/A
- Revenue
- EB $340,111,000.00
- TVTX $177,644,000.00
- Revenue This Year
- EB $1.71
- TVTX $58.99
- Revenue Next Year
- EB $7.04
- TVTX $53.18
- P/E Ratio
- EB N/A
- TVTX N/A
- Revenue Growth
- EB 14.97
- TVTX 47.42
- 52 Week Low
- EB $2.51
- TVTX $5.12
- 52 Week High
- EB $9.20
- TVTX $18.81
- Technical
- Relative Strength Index (RSI)
- EB 47.38
- TVTX 74.30
- Support Level
- EB $2.59
- TVTX $16.17
- Resistance Level
- EB $2.99
- TVTX $18.60
- Average True Range (ATR)
- EB 0.15
- TVTX 1.24
- MACD
- EB 0.04
- TVTX 0.17
- Stochastic Oscillator
- EB 61.25
- TVTX 89.95
About EB Eventbrite Inc.
Eventbrite Inc is a self-service ticketing and experience technology platform that serves event creators. It is engaged in creating a platform to enable creators to solve many challenges associated with creating live experiences. The Company's platform integrates components needed to seamlessly plan, promote and produce live events. Its platform helps to plan, promote and produce live events, thereby allowing creators to reduce friction and costs, increase reach and drive ticket sales. Geographically, it generates maximum revenue from the United States.
About TVTX Travere Therapeutics Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often cause end-stage kidney disease.